XML 52 R35.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Pfizer Inc. (Details) $ in Millions | 1 Months Ended | 12 Months Ended | 76 Months Ended | 83 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2017 USD ($) | May 31, 2017 USD ($) | Dec. 31, 2020 USD ($) | Mar. 31, 2024 USD ($) product milestone | Mar. 31, 2024 USD ($) milestone
Pfizer Inc. |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Agreement termination, term |  | 15 years |  |  |
Pfizer Inc. | S B Five Two Five And Other Products |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Revenues under agreement |  | $ 70.0 |  |  |
Potential amount to be funded for achievement of specified commercialized and sales milestones |  | 266.5 |  |  |
Pfizer Inc. | S B Five Two Five And Other Products | Achievement of specified clinical development intellectual property and regulatory milestones |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Development and sales-based milestone payments to be received |  | 208.5 |  |  |
Pfizer Inc. | S B Five Two Five |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Milestone revenue receivable |  | 220.0 |  |  |
Pfizer Inc. | Other products |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Milestone revenue receivable |  | $ 175.0 |  |  |
Pfizer Inc. | License | Minimum |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Percentage of net sales per developed licensed product which will trigger royalties by counterparty |  | 14.00% |  |  |
Pfizer Inc. | License | Maximum |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Percentage of net sales per developed licensed product which will trigger royalties by counterparty |  | 20.00% |  |  |
Pfizer SB-525 |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Collaborative arrangement transaction price |  |  | $ 134.0 |  |
Pfizer SB-525 | S B Five Two Five And Other Products |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Collaborative arrangement, number of milestones achieved | milestone |  |  |  |  | 2
Milestone payments received |  |  |  |  | $ 55.0
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Agreement termination, term | 15 years |  |  |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Minimum |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Percentage of net sales per developed licensed product which will trigger royalties by counterparty | 14.00% |  |  |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | License | Maximum |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Percentage of net sales per developed licensed product which will trigger royalties by counterparty | 20.00% |  |  |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | C9ORF72 |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Milestone payments received | $ 12.0 |  |  | $ 5.0 |
Collaborative arrangement transaction price | 17.0 |  |  |  |
Number of products approved | product |  |  |  | 0 |
Number of milestones included in transaction price | milestone |  |  |  | 0 |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | C9ORF72 | Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones | Maximum |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Development and sales-based milestone payments to be received | 60.0 |  |  |  |
Alexion Pharmaceuticals, Inc., AstraZeneca Rare Disease | C9ORF72 | Achievement Of Commercial Milestones | Maximum |  |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |  |
Development and sales-based milestone payments to be received | $ 90.0 |  |  |  |

X
- Definition Aggregate additional revenue recognition milestone method revenue eligible to receive. + References No definition available. + Details
Name: | sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Agreement Termination, Term + References No definition available. + Details
Name: | sgmo_AgreementTerminationTerm
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration and license agreements number of products approved under agreement. + References No definition available. + Details
Name: | sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Number Of Milestones Achieved + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementNumberOfMilestonesAchieved
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement transaction price. + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contract With Customer, Eligible Royalties, Triggered By Percentage Of Net Sales Per Developed Licensed Product By Counterparty + References No definition available. + Details
Name: | sgmo_ContractWithCustomerEligibleRoyaltiesTriggeredByPercentageOfNetSalesPerDevelopedLicensedProductByCounterparty
Namespace Prefix: | sgmo_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Customer contract liability milestone payment eligible to receive. + References No definition available. + Details
Name: | sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments received. + References No definition available. + Details
Name: | sgmo_MilestonePaymentsReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone​ revenue receivable. + References No definition available. + Details
Name: | sgmo_MilestoneRevenueReceivable
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of clinical or regulatory milestones included in transaction price. + References No definition available. + Details
Name: | sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveAndOtherProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ManufacturedProductOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_PfizerSB525Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_AlexionPharmaceuticalsInc.AstraZenecaRareDiseaseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |